Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01931787 · ClinicalTrials.gov registry record · Phase 1

CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

A Phase 1 study of Recurrent Small Cell Lung Cancer, sponsored by Wake Forest University Health Sciences.

Completed
Registry status
Phase 1
Development phase
15
Enrollment target
1
Study location

NCT01931787 is a Phase 1 study of Recurrent Small Cell Lung Cancer that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 15 participants, below the 56-participant average among 5 other Recurrent Small Cell Lung Cancer trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01931787, a Phase 1 study of Recurrent Small Cell Lung Cancer, has completed, sponsored by Wake Forest University Health Sciences.

COMPLETED
Registry status
Phase 1
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

This pilot clinical trial studies CPI-613 (6,8-bis\[benzylthio\]octanoic acid) in treating patients with relapsed or refractory small cell lung cancer. CPI-613 may interfere with the growth of tumor cells and may be an effective treatment for small cell lung cancer.

Conditions Studied

Recurrent Small Cell Lung Cancer

Interventions

  • DRUG 6,8-bis(benzylthio)octanoic acid

Study Locations (1)

North Carolina

  • Comprehensive Cancer Center of Wake Forest University - Winston-Salem

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2013-10
Est. Completion 2015-12
Phase Phase 1

Sponsor

Wake Forest University Health Sciences

1,140 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01931787

The ClinicalTrials.gov registry entry for NCT01931787 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 56-participant average among 5 other Recurrent Small Cell Lung Cancer trials with a reported enrollment target (73% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Recurrent Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which 6,8-bis(benzylthio)octanoic acid is the first listed.

NCT01931787 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT01931787 about?

NCT01931787 is a clinical study titled "CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer". This pilot clinical trial studies CPI-613 (6,8-bis\[benzylthio\]octanoic acid) in treating patients with relapsed or refractory small cell lung cancer. CPI-613 may interfere with the growth of tumor cells and may be an effective treatment for small cell lung cancer.

What is the current status of trial NCT01931787?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2013-10. Estimated completion is 2015-12.

What conditions does trial NCT01931787 study?

This clinical trial studies the following conditions: Recurrent Small Cell Lung Cancer.

What interventions are being tested in trial NCT01931787?

The interventions under investigation include: 6,8-bis(benzylthio)octanoic acid (DRUG).

Who is sponsoring clinical trial NCT01931787?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01931787 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Small Cell Lung Cancer

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.